Connection

Don Rockey to Liver Cirrhosis

Back to Details
This is a "connection" page, showing publications Don Rockey has written about Liver Cirrhosis.
Don Rockey
Connection Strength
23.458
Liver Cirrhosis
  1. Improved Mortality But Increased Economic Burden of Disease in Compensated and Decompensated Cirrhosis: A US National Perspective. J Clin Gastroenterol. 2023 03 01; 57(3):300-310.
    View in: PubMed
    Score: 0.656
  2. Role of Liver Biopsy in Assessment of Radiologically Identified Liver Masses. Dig Dis Sci. 2022 01; 67(1):337-343.
    View in: PubMed
    Score: 0.570
  3. Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside. Gastroenterology. 2021 04; 160(5):1502-1520.e1.
    View in: PubMed
    Score: 0.568
  4. Moesin, an Ezrin/Radixin/Moesin Family Member, Regulates Hepatic Fibrosis. Hepatology. 2020 09; 72(3):1073-1084.
    View in: PubMed
    Score: 0.546
  5. Ammonia Levels Do Not Guide Clinical Management of Patients With Hepatic Encephalopathy Caused by Cirrhosis. Am J Gastroenterol. 2020 05; 115(5):723-728.
    View in: PubMed
    Score: 0.539
  6. Cirrhotic Patients on Mechanical Ventilation Have a Low Rate of Successful Extubation and Survival. Dig Dis Sci. 2020 12; 65(12):3744-3752.
    View in: PubMed
    Score: 0.529
  7. Lower Gastrointestinal Bleeding in Patients With Cirrhosis-Etiology and Outcomes. Am J Med Sci. 2020 04; 359(4):206-211.
    View in: PubMed
    Score: 0.528
  8. Sedation During Endoscopy in Patients with Cirrhosis: Safety and Predictors of Adverse Events. Dig Dis Sci. 2020 04; 65(4):1258-1265.
    View in: PubMed
    Score: 0.519
  9. Smooth Muscle a-Actin Deficiency Leads to Decreased Liver Fibrosis via Impaired Cytoskeletal Signaling in Hepatic Stellate Cells. Am J Pathol. 2019 11; 189(11):2209-2220.
    View in: PubMed
    Score: 0.514
  10. Controversies in anticoagulation therapy in patients with cirrhosis. Curr Opin Gastroenterol. 2019 05; 35(3):161-167.
    View in: PubMed
    Score: 0.503
  11. Fibrosis reversal after hepatitis C virus elimination. Curr Opin Gastroenterol. 2019 05; 35(3):137-144.
    View in: PubMed
    Score: 0.503
  12. Anticoagulation Therapy in Patients with Liver Cirrhosis is Associated With an Increased Risk of Variceal Hemorrhage. Am J Med. 2019 06; 132(6):758-766.
    View in: PubMed
    Score: 0.493
  13. Evaluation of abnormal liver tests in the adult asymptomatic patient. Curr Opin Gastroenterol. 2018 07; 34(4):272-279.
    View in: PubMed
    Score: 0.475
  14. Predictors of clinical outcomes in cirrhosis patients. Curr Opin Gastroenterol. 2018 07; 34(4):266-271.
    View in: PubMed
    Score: 0.475
  15. Development of a novel clinical staging model for cirrhosis using the Nationwide Inpatient Sample. J Investig Med. 2018 08; 66(6):992-997.
    View in: PubMed
    Score: 0.470
  16. Infection-Related Mortality in Patients With Cirrhosis. Am J Med Sci. 2018 Feb; 355(2):102-103.
    View in: PubMed
    Score: 0.461
  17. The Molecular Basis of Portal Hypertension. Trans Am Clin Climatol Assoc. 2017; 128:330-345.
    View in: PubMed
    Score: 0.428
  18. Liver Fibrosis Reversion After Suppression of Hepatitis B Virus. Clin Liver Dis. 2016 11; 20(4):667-679.
    View in: PubMed
    Score: 0.423
  19. A New Treatment for Portal Hypertension? Gastroenterology. 2016 05; 150(5):1077-1080.
    View in: PubMed
    Score: 0.406
  20. Point-of-Care Echocardiography Improves Assessment of Volume Status in Cirrhosis and Hepatorenal Syndrome. Am J Med Sci. 2016 May; 351(5):550-3.
    View in: PubMed
    Score: 0.404
  21. Overuse of Head Computed Tomography in Cirrhosis With Altered Mental Status. Am J Med Sci. 2016 05; 351(5):459-66.
    View in: PubMed
    Score: 0.403
  22. Hepatic Encephalopathy: Pharmacological Therapies Targeting Ammonia. Semin Liver Dis. 2016 Feb; 36(1):48-55.
    View in: PubMed
    Score: 0.402
  23. Caveolin-1 is upregulated in hepatic stellate cells but not sinusoidal endothelial cells after liver injury. Tissue Cell. 2016 Apr; 48(2):126-32.
    View in: PubMed
    Score: 0.399
  24. Renal dysfunction in cirrhosis. Curr Opin Gastroenterol. 2015 May; 31(3):215-23.
    View in: PubMed
    Score: 0.381
  25. Age and ethnicity in cirrhosis. J Investig Med. 2014 Oct; 62(7):920-6.
    View in: PubMed
    Score: 0.366
  26. A risk scoring system to predict in-hospital mortality in patients with cirrhosis presenting with upper gastrointestinal bleeding. J Clin Gastroenterol. 2014 Sep; 48(8):712-20.
    View in: PubMed
    Score: 0.364
  27. Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions. J Hepatol. 2014 Oct; 61(4):912-24.
    View in: PubMed
    Score: 0.358
  28. Hepatic hydrothorax: clinical features, management, and outcomes in 77 patients and review of the literature. Medicine (Baltimore). 2014 May; 93(3):135-142.
    View in: PubMed
    Score: 0.356
  29. Clinical utility of a standardized electronic order set for the management of acute upper gastrointestinal hemorrhage in patients with cirrhosis. Clin Gastroenterol Hepatol. 2013 Oct; 11(10):1342-8.
    View in: PubMed
    Score: 0.332
  30. Altered mental status in cirrhosis: etiologies and outcomes. J Investig Med. 2013 Apr; 61(4):695-700.
    View in: PubMed
    Score: 0.330
  31. Hemorrhagic ascites. Clinical presentation and outcomes in patients with cirrhosis. J Hepatol. 2013 Jun; 58(6):1113-8.
    View in: PubMed
    Score: 0.326
  32. Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies. Clin Gastroenterol Hepatol. 2013 Mar; 11(3):224-31.e1-5.
    View in: PubMed
    Score: 0.325
  33. Complications of cirrhosis. Curr Opin Gastroenterol. 2012 May; 28(3):223-9.
    View in: PubMed
    Score: 0.310
  34. Acute kidney injury and chronic kidney disease in hospitalized patients with cirrhosis. J Investig Med. 2011 Dec; 59(8):1244-51.
    View in: PubMed
    Score: 0.301
  35. Effectiveness of the PPAR? agonist, GW570, in liver fibrosis. Inflamm Res. 2010 Dec; 59(12):1061-71.
    View in: PubMed
    Score: 0.272
  36. Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis. 2008 Nov; 12(4):939-62, xi.
    View in: PubMed
    Score: 0.243
  37. Effect of the nitric oxide donor V-PYRRO/NO on portal pressure and sinusoidal dynamics in normal and cirrhotic mice. Am J Physiol Gastrointest Liver Physiol. 2008 Jun; 294(6):G1311-7.
    View in: PubMed
    Score: 0.233
  38. Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography. Gastroenterology. 2008 Jan; 134(1):8-14.
    View in: PubMed
    Score: 0.229
  39. New therapies in hepatitis C virus and chronic liver disease: antifibrotics. Clin Liver Dis. 2006 Nov; 10(4):881-900.
    View in: PubMed
    Score: 0.211
  40. Hepatic fibrosis, stellate cells, and portal hypertension. Clin Liver Dis. 2006 Aug; 10(3):459-79, vii-viii.
    View in: PubMed
    Score: 0.208
  41. Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2006 Nov; 291(5):G902-11.
    View in: PubMed
    Score: 0.206
  42. Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. J Viral Hepat. 2006 May; 13(5):322-8.
    View in: PubMed
    Score: 0.204
  43. Noninvasive measures of liver fibrosis. Hepatology. 2006 Feb; 43(2 Suppl 1):S113-20.
    View in: PubMed
    Score: 0.201
  44. Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol. 2005 Feb; 3(2):95-107.
    View in: PubMed
    Score: 0.187
  45. An AI Approach for Identifying Patients With Cirrhosis. J Clin Gastroenterol. 2023 Jan 01; 57(1):82-88.
    View in: PubMed
    Score: 0.162
  46. Dosing of Rifaximin Soluble Solid Dispersion Tablets in Adults With Cirrhosis: 2 Randomized, Placebo-controlled Trials. Clin Gastroenterol Hepatol. 2023 03; 21(3):723-731.e9.
    View in: PubMed
    Score: 0.156
  47. Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy. Hepatology. 2002 May; 35(5):1022-30.
    View in: PubMed
    Score: 0.155
  48. Imaging Mass Spectrometry Reveals Alterations in N-Linked Glycosylation That Are Associated With Histopathological Changes in Nonalcoholic Steatohepatitis in Mouse and Human. Mol Cell Proteomics. 2022 05; 21(5):100225.
    View in: PubMed
    Score: 0.154
  49. Bleeding ectopic varices: clinical presentation, natural history, and outcomes. J Investig Med. 2022 06; 70(5):1280-1284.
    View in: PubMed
    Score: 0.153
  50. Infection in Hospitalized Cirrhosis Patients: Changing Epidemiology and Clinical Features. Am J Med Sci. 2022 02; 363(2):114-121.
    View in: PubMed
    Score: 0.151
  51. The relationship between portal hypertension and portal hypertensive gastropathy. Scand J Gastroenterol. 2022 Mar; 57(3):340-344.
    View in: PubMed
    Score: 0.151
  52. A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis. Hepatology. 2021 12; 74(6):3146-3160.
    View in: PubMed
    Score: 0.150
  53. Normal or near normal aminotransferase levels in patients with alcoholic cirrhosis. Am J Med Sci. 2022 06; 363(6):484-489.
    View in: PubMed
    Score: 0.149
  54. Letter to the Editor: Complications Associated With Anesthesia Services in Endoscopic Procedures Among Patients With Cirrhosis. Hepatology. 2021 10; 74(4):2313-2314.
    View in: PubMed
    Score: 0.148
  55. Hepatitis C virus treatment with direct-acting antivirals induces rapid changes in the hepatic proteome. J Viral Hepat. 2021 11; 28(11):1614-1623.
    View in: PubMed
    Score: 0.147
  56. Letter: Confounders and outcomes in studies of beta-blockers in liver disease-role of PPIs? Authors' reply. Aliment Pharmacol Ther. 2021 07; 54(1):91.
    View in: PubMed
    Score: 0.146
  57. Statins for treatment of chronic liver disease. Curr Opin Gastroenterol. 2021 05 01; 37(3):200-207.
    View in: PubMed
    Score: 0.144
  58. Updated strategies in the management of acute variceal haemorrhage. Curr Opin Gastroenterol. 2021 05 01; 37(3):167-172.
    View in: PubMed
    Score: 0.144
  59. Advanced liver fibrosis and the metabolic syndrome in a primary care setting. Diabetes Metab Res Rev. 2021 11; 37(8):e3452.
    View in: PubMed
    Score: 0.144
  60. Editorial: non-selective beta blockers-in and out of circulation. Authors' reply. Aliment Pharmacol Ther. 2021 03; 53(5):634-635.
    View in: PubMed
    Score: 0.143
  61. From Coronaries to Cirrhosis: The Role of Percutaneous Coronary Intervention and Dual Antiplatelet Therapy in End-Stage Liver Disease. J Investig Med High Impact Case Rep. 2021 Jan-Dec; 9:23247096211005097.
    View in: PubMed
    Score: 0.141
  62. Non-selective beta-blocker use in cirrhotic patients is associated with a reduced likelihood of hospitalisation for infection. Aliment Pharmacol Ther. 2021 02; 53(3):418-425.
    View in: PubMed
    Score: 0.141
  63. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy. Gastroenterology. 2000 Jun; 118(6):1261-5.
    View in: PubMed
    Score: 0.136
  64. Clinical course of COVID-19 in patients with pre-existing decompensated cirrhosis: initial report from China. Hepatol Int. 2020 Jul; 14(4):478-482.
    View in: PubMed
    Score: 0.135
  65. The cell and molecular biology of hepatic fibrogenesis. Clinical and therapeutic implications. Clin Liver Dis. 2000 May; 4(2):319-55.
    View in: PubMed
    Score: 0.135
  66. Variability and Lability of Ammonia Levels in Healthy Volunteers and Patients With Cirrhosis: Implications for Trial Design and Clinical Practice. Am J Gastroenterol. 2020 05; 115(5):783-785.
    View in: PubMed
    Score: 0.135
  67. Hepatic fibrogenesis and hepatitis C. Semin Gastrointest Dis. 2000 Apr; 11(2):69-83.
    View in: PubMed
    Score: 0.134
  68. Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites. Am J Gastroenterol. 2000 Jan; 95(1):199-203.
    View in: PubMed
    Score: 0.132
  69. Aldehyde dehydrogenase-2 activation by Alda-1 decreases necrosis and fibrosis after bile duct ligation in mice. Free Radic Biol Med. 2019 12; 145:136-145.
    View in: PubMed
    Score: 0.129
  70. An Update: Portal Hypertensive Gastropathy and Colopathy. Clin Liver Dis. 2019 11; 23(4):643-658.
    View in: PubMed
    Score: 0.129
  71. Editorial: Advances in Hepatology: 2019. Curr Opin Gastroenterol. 2019 05; 35(3):135-136.
    View in: PubMed
    Score: 0.126
  72. Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension. Hepatology. 2019 03; 69(3):1287-1299.
    View in: PubMed
    Score: 0.124
  73. Cirrhotic ascites, ovarian carcinoma, and CA-125. South Med J. 1999 Feb; 92(2):248-50.
    View in: PubMed
    Score: 0.124
  74. Trends in Hospitalization, Acute Kidney Injury, and Mortality in Patients With Spontaneous Bacterial Peritonitis. J Clin Gastroenterol. 2019 02; 53(2):e68-e74.
    View in: PubMed
    Score: 0.124
  75. Screening for esophageal varices in patients with hepatocellular carcinoma. Gastrointest Endosc. 2018 08; 88(2):240-241.
    View in: PubMed
    Score: 0.119
  76. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. Gastroenterology. 2018 10; 155(4):1140-1153.
    View in: PubMed
    Score: 0.119
  77. Endothelin in hepatic fibrosis--friend or foe? Hepatology. 1996 Jun; 23(6):1698-700.
    View in: PubMed
    Score: 0.103
  78. Acute on chronic liver failure: definitions, treatments and outcomes. Curr Opin Gastroenterol. 2016 May; 32(3):172-81.
    View in: PubMed
    Score: 0.102
  79. Prediction of esophageal varices and variceal hemorrhage in patients with acute upper gastrointestinal bleeding. J Investig Med. 2016 Mar; 64(3):745-51.
    View in: PubMed
    Score: 0.101
  80. Prospective Multicenter Observational Study of Overt Hepatic Encephalopathy. Dig Dis Sci. 2016 06; 61(6):1728-34.
    View in: PubMed
    Score: 0.100
  81. Fasting Blood Ammonia Predicts Risk and Frequency of Hepatic Encephalopathy Episodes in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2016 06; 14(6):903-906.e1.
    View in: PubMed
    Score: 0.100
  82. Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern Med. 2014 Nov; 174(11):1727-33.
    View in: PubMed
    Score: 0.092
  83. Worldwide practices for pharmacologic therapy in esophageal variceal hemorrhage. Scand J Gastroenterol. 2014 Feb; 49(2):131-7.
    View in: PubMed
    Score: 0.086
  84. Use of administrative claims data for identifying patients with cirrhosis. J Clin Gastroenterol. 2013 May-Jun; 47(5):e50-4.
    View in: PubMed
    Score: 0.083
  85. Current opinion in gastroenterology. Editorial. Curr Opin Gastroenterol. 2013 May; 29(3):241-2.
    View in: PubMed
    Score: 0.083
  86. An automated model using electronic medical record data identifies patients with cirrhosis at high risk for readmission. Clin Gastroenterol Hepatol. 2013 Oct; 11(10):1335-1341.e1.
    View in: PubMed
    Score: 0.083
  87. Treatment of hepatitis C by primary care providers. N Engl J Med. 2011 09 08; 365(10):959-60; author reply 960.
    View in: PubMed
    Score: 0.074
  88. Adiponectin regulation of stellate cell activation via PPAR?-dependent and -independent mechanisms. Am J Pathol. 2011 Jun; 178(6):2690-9.
    View in: PubMed
    Score: 0.073
  89. Adherence and adequacy of therapy for esophageal varices prophylaxis. Dig Dis Sci. 2011 Nov; 56(11):3129-36.
    View in: PubMed
    Score: 0.073
  90. Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology. 2010 Apr; 138(4):1365-73, 1373.e1-2.
    View in: PubMed
    Score: 0.066
  91. Using capsule endoscopy to identify GI tract lesions in cirrhotic patients with portal hypertension and chronic anemia. J Clin Gastroenterol. 2008 Aug; 42(7):844-8.
    View in: PubMed
    Score: 0.060
  92. Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. Clin Gastroenterol Hepatol. 2008 Feb; 6(2):242-7.
    View in: PubMed
    Score: 0.057
  93. Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection. J Transl Med. 2007 Jul 11; 5:33.
    View in: PubMed
    Score: 0.055
  94. Hepatic fibrosis 2006: report of the Third AASLD Single Topic Conference. Hepatology. 2007 Jan; 45(1):242-9.
    View in: PubMed
    Score: 0.053
  95. Pharmacologic therapy for gastrointestinal bleeding due to portal hypertension and esophageal varices. Curr Gastroenterol Rep. 2006 Feb; 8(1):7-13.
    View in: PubMed
    Score: 0.050
  96. In pursuit of the "Holy Grail"--stem cells, hepatic injury, fibrogenesis and repair. Hepatology. 2005 Jan; 41(1):16-8.
    View in: PubMed
    Score: 0.047
  97. Review article: controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis. Aliment Pharmacol Ther. 2023 Mar; 57(5):454-463.
    View in: PubMed
    Score: 0.041
  98. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology. 2002 Apr; 35(4):762-71.
    View in: PubMed
    Score: 0.038
  99. GlycoFibroTyper: A Novel Method for the Glycan Analysis of IgG and the Development of a Biomarker Signature of Liver Fibrosis. Front Immunol. 2022; 13:797460.
    View in: PubMed
    Score: 0.038
  100. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. Drug Saf. 2021 02; 44(2):133-165.
    View in: PubMed
    Score: 0.035
  101. Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study. Gut. 2021 02; 70(2):433-436.
    View in: PubMed
    Score: 0.034
  102. Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding. Aliment Pharmacol Ther. 2020 02; 51(3):364-373.
    View in: PubMed
    Score: 0.033
  103. New concepts in the pathogenesis of portal hypertension: hepatic wounding and stellate cell contractility. Clin Liver Dis. 1997 May; 1(1):13-29.
    View in: PubMed
    Score: 0.027
  104. Hepatorenal Acute Kidney Injury and the Importance of Raising Mean Arterial Pressure. Nephron. 2015; 131(3):191-201.
    View in: PubMed
    Score: 0.025
  105. The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci. 2007 Feb; 52(2):589-93.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.